DK3181691T3 - Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme - Google Patents
Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme Download PDFInfo
- Publication number
- DK3181691T3 DK3181691T3 DK17152168.5T DK17152168T DK3181691T3 DK 3181691 T3 DK3181691 T3 DK 3181691T3 DK 17152168 T DK17152168 T DK 17152168T DK 3181691 T3 DK3181691 T3 DK 3181691T3
- Authority
- DK
- Denmark
- Prior art keywords
- same
- pharmaceutical composition
- composition including
- fgf23 antibody
- fgf23
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Neurology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007034018 | 2007-02-14 | ||
EP12170984.4A EP2502996B1 (en) | 2007-02-14 | 2008-02-14 | Anti-FGF23 antibody and pharmaceutical composition comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3181691T3 true DK3181691T3 (da) | 2020-08-17 |
Family
ID=39690189
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12170984.4T DK2502996T3 (da) | 2007-02-14 | 2008-02-14 | Anti-FGF23-antistof og farmaceutisk sammensætning omfattende samme |
DK17152168.5T DK3181691T3 (da) | 2007-02-14 | 2008-02-14 | Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme |
DK08711707.3T DK2128253T3 (da) | 2007-02-14 | 2008-02-14 | Anti-fgf23-antistof og farmaceutisk sammensætning omfattende samme |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12170984.4T DK2502996T3 (da) | 2007-02-14 | 2008-02-14 | Anti-FGF23-antistof og farmaceutisk sammensætning omfattende samme |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08711707.3T DK2128253T3 (da) | 2007-02-14 | 2008-02-14 | Anti-fgf23-antistof og farmaceutisk sammensætning omfattende samme |
Country Status (23)
Country | Link |
---|---|
US (4) | US7883705B2 (da) |
EP (3) | EP2128253B1 (da) |
JP (1) | JP4800396B2 (da) |
KR (1) | KR101462291B1 (da) |
CN (2) | CN102702355B (da) |
AU (1) | AU2008215346B2 (da) |
CA (1) | CA2677782C (da) |
CY (3) | CY1118835T1 (da) |
DK (3) | DK2502996T3 (da) |
ES (3) | ES2811318T3 (da) |
FR (1) | FR18C1032I2 (da) |
HK (2) | HK1140228A1 (da) |
HR (2) | HRP20170548T1 (da) |
HU (3) | HUE050517T2 (da) |
LT (3) | LT3181691T (da) |
LU (2) | LUC00081I2 (da) |
NL (1) | NL300945I2 (da) |
NO (1) | NO2018025I1 (da) |
PL (3) | PL2128253T3 (da) |
PT (3) | PT2502996T (da) |
SI (2) | SI2502996T1 (da) |
TW (1) | TWI422593B (da) |
WO (1) | WO2008099969A1 (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2344679T3 (es) * | 2000-08-11 | 2010-09-03 | Kyowa Hakko Kirin Co., Ltd. | Polipeptidos que controlan el metabolismo del acido fosforico, el metabolismo del calcio, el metabolismo de la calcificacion y de la vitamina d y moleculas de adn que los codifican. |
KR101016476B1 (ko) * | 2001-12-28 | 2011-02-24 | 교와 핫꼬 기린 가부시키가이샤 | 섬유아세포 증식 인자-23에 대한 항체 |
US7883705B2 (en) * | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
WO2012050673A1 (en) * | 2010-10-14 | 2012-04-19 | Wisconsin Alumni Research Foundation | Methods for the treatment of x-linked hypophosphatemia and related disorders |
US20140294820A1 (en) | 2011-06-24 | 2014-10-02 | University Of Miami | Fibroblast growth factor receptor inhibition for the treatment of disease |
BR112016028567A2 (pt) * | 2014-06-09 | 2018-01-30 | Kyowa Hakko Kirin Co Ltd | método para utilizar ligante anti-fgf23 e para tratar doença e/ou condição relacionada com fgf23 e para aumentar a remodelação óssea |
WO2018069232A1 (en) | 2016-10-10 | 2018-04-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of having cardiac hypertrophy |
JP7023932B2 (ja) | 2017-03-30 | 2022-02-22 | シスメックス株式会社 | 抗ApoA1抗体 |
AU2020253833A1 (en) * | 2019-03-29 | 2021-10-28 | Atarga, Llc | Anti FGF23 antibody |
TW202413406A (zh) * | 2022-08-10 | 2024-04-01 | 日商協和麒麟股份有限公司 | 抗fgf23抗體或該抗體片段 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5623587A (en) | 1979-08-03 | 1981-03-05 | Mitsuwa Seiki Co Ltd | Vane type compressor |
WO1985003934A1 (en) | 1984-03-06 | 1985-09-12 | Takeda Chemical Industries, Ltd. | Chemically modified protein and process for its preparation |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS61178926U (da) | 1985-04-23 | 1986-11-08 | ||
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
FI884924A (fi) | 1987-10-28 | 1989-04-29 | Oncogen | Humanimmuglobulin som producerats med hybrid-dna-teknik. |
JP2958019B2 (ja) | 1988-05-06 | 1999-10-06 | 住友製薬株式会社 | ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5958879A (en) * | 1989-10-12 | 1999-09-28 | Ohio University/Edison Biotechnology Institute | Growth hormone receptor antagonists and methods of reducing growth hormone activity in a mammal |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6001358A (en) | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
JP4424575B2 (ja) | 1998-05-18 | 2010-03-03 | ユニバーシティー カレッジ ロンドン | 新規ポリペプチドホルモン・フォスファトニン |
TWI255853B (en) | 1998-08-21 | 2006-06-01 | Kirin Brewery | Method for modifying chromosomes |
WO2000060085A1 (en) | 1999-04-02 | 2000-10-12 | Millennium Pharmaceuticals, Inc. | Fibroblast growth factor-20 |
US6596849B1 (en) * | 1999-05-28 | 2003-07-22 | Academia Sinica | Monoclonal-antibody for analysis and clearance of polyethylene glycol and polyethylene glycol-modified molecules |
JP2004522402A (ja) | 1999-06-02 | 2004-07-29 | ジェネンテック・インコーポレーテッド | 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸 |
AU2055401A (en) | 1999-12-01 | 2001-06-12 | Genentech Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
WO2001042451A2 (en) | 1999-12-08 | 2001-06-14 | Genset | FULL-LENGTH HUMAN cDNAs ENCODING POTENTIALLY SECRETED PROTEINS |
WO2001049740A1 (en) | 2000-01-05 | 2001-07-12 | Zymogenetics, Inc. | Novel fgf homolog zfgf12 |
JP2003523190A (ja) | 2000-02-14 | 2003-08-05 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
CA2398603A1 (en) | 2000-02-15 | 2001-08-23 | Amgen, Inc. | Fibroblast growth factor-23 molecules and uses thereof |
US20060160181A1 (en) * | 2000-02-15 | 2006-07-20 | Amgen Inc. | Fibroblast Growth Factor-23 molecules and uses thereof |
JP2003531583A (ja) | 2000-03-08 | 2003-10-28 | カイロン コーポレイション | ヒトfgf−23遺伝子および遺伝子発現産物 |
WO2001066596A2 (en) | 2000-03-08 | 2001-09-13 | Chiron Corporation | Human fgf-23 gene and gene expression products |
CA2418215A1 (en) | 2000-07-19 | 2002-01-31 | Advanced Research & Technology Institute | Novel fibroblast growth factor (fgf23) and methods for use |
ES2344679T3 (es) | 2000-08-11 | 2010-09-03 | Kyowa Hakko Kirin Co., Ltd. | Polipeptidos que controlan el metabolismo del acido fosforico, el metabolismo del calcio, el metabolismo de la calcificacion y de la vitamina d y moleculas de adn que los codifican. |
IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
WO2002076467A1 (en) | 2001-03-22 | 2002-10-03 | Genzyme Corporation | Compositions and methods to regulate bone and mineral metabolism |
AU2002302581A1 (en) | 2001-04-26 | 2002-11-11 | Geneprot, Inc. | Human fibroblast growth factor-related compositions |
EP2011802A3 (en) * | 2001-04-27 | 2009-04-15 | Kyowa Hakko Kirin Co., Ltd. | Anti-CD40 monoclonal antibody |
KR101016476B1 (ko) * | 2001-12-28 | 2011-02-24 | 교와 핫꼬 기린 가부시키가이샤 | 섬유아세포 증식 인자-23에 대한 항체 |
US7094551B2 (en) * | 2002-09-17 | 2006-08-22 | Zahradnik Richard J | Immunoassays, assay methods, antibodies and method of creating antibodies for detecting FGF-23 |
US20070036734A1 (en) * | 2003-03-17 | 2007-02-15 | Kirin Beer Kabushiki Kaisha | Therapeutic agent for periodontal disease |
BRPI0511782B8 (pt) * | 2004-06-03 | 2021-05-25 | Novimmune Sa | anticorpos anti-cd3, uso e método de produção dos mesmos, composição farmacêutica, molécula de ácido nucleico isolada e vetor |
PL1773885T3 (pl) * | 2004-08-05 | 2010-09-30 | Genentech Inc | Humanizowani antagoniści anty c-met |
EP2145954A1 (en) * | 2004-09-06 | 2010-01-20 | Kyowa Hakko Kirin Co., Ltd. | Anti-A33 antibody |
WO2006078072A1 (ja) | 2005-01-21 | 2006-07-27 | Kirin Beer Kabushiki Kaisha | キメラ非ヒト動物およびその使用 |
US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
WO2008092019A1 (en) * | 2007-01-25 | 2008-07-31 | Mayo Foundation For Medical Education And Research | Fgf-23 polypeptides |
US7883705B2 (en) * | 2007-02-14 | 2011-02-08 | Kyowa Hakko Kirin Co., Ltd. | Anti FGF23 antibody and a pharmaceutical composition comprising the same |
-
2008
- 2008-02-13 US US12/030,593 patent/US7883705B2/en active Active
- 2008-02-14 EP EP08711707.3A patent/EP2128253B1/en active Active
- 2008-02-14 DK DK12170984.4T patent/DK2502996T3/da active
- 2008-02-14 PT PT121709844T patent/PT2502996T/pt unknown
- 2008-02-14 PL PL08711707T patent/PL2128253T3/pl unknown
- 2008-02-14 PL PL12170984T patent/PL2502996T3/pl unknown
- 2008-02-14 ES ES17152168T patent/ES2811318T3/es active Active
- 2008-02-14 CN CN201210161119.8A patent/CN102702355B/zh active Active
- 2008-02-14 CN CN2008800048145A patent/CN101652476B/zh active Active
- 2008-02-14 EP EP12170984.4A patent/EP2502996B1/en active Active
- 2008-02-14 PT PT171521685T patent/PT3181691T/pt unknown
- 2008-02-14 LU LU00081C patent/LUC00081I2/en unknown
- 2008-02-14 AU AU2008215346A patent/AU2008215346B2/en active Active
- 2008-02-14 DK DK17152168.5T patent/DK3181691T3/da active
- 2008-02-14 CA CA2677782A patent/CA2677782C/en active Active
- 2008-02-14 WO PCT/JP2008/052918 patent/WO2008099969A1/ja active Application Filing
- 2008-02-14 EP EP17152168.5A patent/EP3181691B1/en active Active
- 2008-02-14 ES ES12170984T patent/ES2625823T3/es active Active
- 2008-02-14 DK DK08711707.3T patent/DK2128253T3/da active
- 2008-02-14 LT LTEP17152168.5T patent/LT3181691T/lt unknown
- 2008-02-14 PL PL17152168T patent/PL3181691T3/pl unknown
- 2008-02-14 SI SI200831797T patent/SI2502996T1/sl unknown
- 2008-02-14 HU HUE17152168A patent/HUE050517T2/hu unknown
- 2008-02-14 LT LTEP12170984.4T patent/LT2502996T/lt unknown
- 2008-02-14 SI SI200832131T patent/SI3181691T1/sl unknown
- 2008-02-14 HU HUE12170984A patent/HUE031728T2/en unknown
- 2008-02-14 ES ES08711707T patent/ES2530670T3/es active Active
- 2008-02-14 PT PT87117073T patent/PT2128253E/pt unknown
- 2008-02-14 KR KR1020097019085A patent/KR101462291B1/ko active Protection Beyond IP Right Term
- 2008-02-14 JP JP2008558165A patent/JP4800396B2/ja active Active
- 2008-02-14 TW TW097105234A patent/TWI422593B/zh active
- 2008-02-14 LU LU00082C patent/LUC00082I2/en unknown
-
2010
- 2010-06-28 HK HK10106310.8A patent/HK1140228A1/xx unknown
-
2011
- 2011-02-02 US US13/019,557 patent/US9290569B2/en active Active
-
2013
- 2013-01-04 HK HK13100123.5A patent/HK1172917A1/xx unknown
-
2016
- 2016-02-10 US US15/040,103 patent/US10202446B2/en active Active
-
2017
- 2017-04-04 HR HRP20170548TT patent/HRP20170548T1/hr unknown
- 2017-04-19 CY CY20171100446T patent/CY1118835T1/el unknown
-
2018
- 2018-07-27 NL NL300945C patent/NL300945I2/en unknown
- 2018-07-27 FR FR18C1032C patent/FR18C1032I2/fr active Active
- 2018-08-01 LT LTPA2018508C patent/LTC2502996I2/lt unknown
- 2018-08-02 HU HUS1800034C patent/HUS1800034I1/hu unknown
- 2018-08-07 CY CY2018021C patent/CY2018021I2/el unknown
- 2018-08-09 NO NO2018025C patent/NO2018025I1/no unknown
- 2018-12-18 US US16/223,930 patent/US20190106485A1/en not_active Abandoned
-
2020
- 2020-08-03 CY CY20201100713T patent/CY1123240T1/el unknown
- 2020-08-11 HR HRP20201266TT patent/HRP20201266T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTC2140867I2 (lt) | Farmacinė kompozicija | |
DK2118140T3 (da) | Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf | |
DK1884242T3 (da) | Farmaceutisk sammensætning omfattende lurasidon | |
DK2059535T3 (da) | Prlr-specifikt antistof og anvendelser deraf | |
CY2015013I2 (el) | Αντι-μολυσματικες πυραμιδινες και χρησεις αυτων | |
DK2079485T3 (da) | Phenylpropionamidforbindelser og anvendelsen deraf | |
DK2061814T3 (da) | Antistoffer og immunokonjugater og anvendelse deraf. | |
DK2209806T3 (da) | Anti-hepcidin-antistoffer og anvendelser deraf | |
DK3181691T3 (da) | Anti-fgf23-antistof og en farmaceutisk sammensætning omfattende samme | |
BRPI0717367A2 (pt) | Di-hidropirazolonas substituídas e sua aplicação. | |
BRPI0715712A2 (pt) | Composição farmacêutica | |
DK1894567T3 (da) | Ledsagende farmaceutiske midler og anvendelse deraf | |
DK1957073T3 (da) | Lægemiddel | |
BRPI0721651A2 (pt) | Composição farmacêutica | |
BRPI0714539A2 (pt) | "formas farmacêuticas" | |
BRPI0719393A2 (pt) | Composição farmacêutica | |
DK2170827T3 (da) | Indolin-2-oner og aza-indolin-2-oner | |
DK2001556T3 (da) | Thioninium-forbindelser og anvendelse deraf | |
BRPI0716445A2 (pt) | composiÇço farmacÊutica | |
BRPI0720234A2 (pt) | Composição farmacêutica | |
DK2207773T3 (da) | Heterocyklisk forbindelse og farmaceutisk sammensætning deraf. | |
ATE493119T1 (de) | Pharmazeutische zusammensetzung | |
DE602008005137D1 (de) | Chinolonverbindung und pharmazeutische zusammensetzung | |
DK2029561T3 (da) | Tricyclisk forbindelse og farmaceutisk anvendelse deraf | |
DK2231603T3 (da) | Substituerede 3-hydroxypyridiner og farmaceutiske sammensætninger deraf |